Adva-27a is one of a kind. I believe this is where a chunk of the value is coming from. They need to start phase one of it, but they aren't until mid 2018 due to lack of fundimg. They even say a huge buyout is possible in the filings if phase 1 is a success.
"Unlike Etoposide, and other anti-tumor drugs currently in use, Adva-27a is able to destroy Multidrug Resistant Cancer cells. Adva-27a is the only compound known today that is capable of destroying Multidrug Resistant Cancer. "
Until then, they will try to distribute the other drugs they have a generic patent for.
News 
Market Data 
Discover 
